Semaglutide vs Tirzepatide vs Retatrutide: A Data-Driven Comparison

The GLP-1 Generation Gap

In less than a decade, incretin-based peptide therapy went from a niche diabetes treatment to one of the most commercially significant drug classes in pharmaceutical history. Three compounds define the current landscape:

Semaglutide — GLP-1 receptor agonist, FDA-approved 2017 (diabetes) and 2021 (weight management)
Tirzepatide — dual GLP-1/GIP receptor agonist, FDA-approved 2022 (diabetes) and 2023 (weight management)
Retatrutide — triple GLP-1/GIP/glucagon receptor agonist, currently in Phase 3 trials

Each generation adds a receptor target and, with it, incrementally greater efficacy. Understanding the differences matters whether you're a patient choosing between options, a clinician prescribing them, or someone trying to understand where this drug class is heading.

You can compare any two of these directly on our Compare tool.

Mechanism: What Each One Does

Semaglutide — Single Agonist

Semaglutide activates the GLP-1 receptor (glucagon-like peptide-1). GLP-1 is a hormone naturally released by the gut after eating. Activating its receptor:

Stimulates insulin secretion in response to glucose
Suppresses glucagon (which would otherwise raise blood sugar)
Slows gastric emptying (food moves through the stomach more slowly)
Signals the brain to reduce appetite

The result: lower blood sugar, reduced appetite, and significant weight loss. Semaglutide's weekly injection format (vs. the daily injections of earlier GLP-1 drugs) was a major practical improvement that drove adoption.

Tirzepatide — Dual Agonist

Tirzepatide activates both GLP-1 and GIP receptors (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone that:

Enhances insulin secretion (additive with GLP-1 effects)
Promotes fat storage in adipose tissue at physiological levels — but at pharmacological doses, appears to enhance fat oxidation
May reduce the GI side effects that limit GLP-1 monotherapy

The dual mechanism produces greater weight loss than semaglutide in head-to-head data, with a potentially more tolerable side effect profile for some patients.

Retatrutide — Triple Agonist

Retatrutide adds glucagon receptor activation to the GLP-1/GIP combination. Glucagon:

Increases energy expenditure (thermogenesis)
Promotes fat oxidation in the liver
Raises blood sugar — which sounds counterproductive, but at the doses used, the GLP-1/GIP insulin effects dominate

The triple mechanism targets weight loss through three simultaneous pathways: appetite suppression (GLP-1), enhanced metabolic efficiency (GIP), and increased energy expenditure (glucagon). Phase 2 data showed weight loss exceeding anything seen with single or dual agonists.

Efficacy: What the Trials Show

Weight Loss

| Compound | Trial | Duration | Average Weight Loss | |---|---|---|---| | Semaglutide 2.4mg | STEP 1 | 68 weeks | 14.9% body weight | | Tirzepatide 15mg | SURMOUNT-1 | 72 weeks | 20.9% body weight | | Retatrutide 12mg | Phase 2 | 48 weeks | 24.2% body weight |

These are not directly comparable — different trial designs, populations, and durations. But the directional trend is clear: each generation produces meaningfully greater weight loss.

For context: lifestyle intervention alone typically produces 3–5% weight loss. Older weight loss medications produced 5–10%. These compounds represent a step-change in what pharmacological weight management can achieve.

Blood Sugar Control (HbA1c Reduction)

All three are effective for type 2 diabetes. Tirzepatide showed superior HbA1c reduction vs. semaglutide in the SURPASS-2 head-to-head trial (−2.01% vs. −1.86% at 40 weeks). Retatrutide data in diabetes is still emerging from Phase 3.

Cardiovascular Outcomes

Semaglutide has the strongest cardiovascular evidence — the SELECT trial (2023) showed a 20% reduction in major cardiovascular events in non-diabetic patients with obesity. This was a landmark finding that expanded the indication beyond metabolic control.

Tirzepatide cardiovascular outcome data (SURMOUNT-MMO trial) is expected in 2026. Retatrutide cardiovascular data is years away.

Side Effects: The Real-World Picture

All three share a common GI side effect profile driven by the GLP-1 mechanism:

Common (all three):

Nausea — most common, typically worst during dose escalation
Vomiting
Diarrhea or constipation
Decreased appetite (partly the intended effect)

Serious but rare (all three):

Pancreatitis
Gallbladder disease (gallstones, cholecystitis)
Thyroid C-cell tumors (animal data — human risk unclear, contraindicated with personal/family history of medullary thyroid cancer)

Tirzepatide vs. Semaglutide: Some clinical experience suggests tirzepatide may have a slightly more tolerable GI profile for some patients, possibly due to the GIP component modulating GI motility differently. This is not definitively established in trial data.

Retatrutide: Phase 2 data showed similar GI side effects to the other two. The glucagon component adds a theoretical concern about blood sugar elevation, but this was not clinically significant in trials at the doses studied.

Muscle loss: All three cause some loss of lean mass alongside fat loss — a concern for older patients and those focused on body composition. Combining with resistance training and adequate protein intake is consistently recommended.

Access and Cost

Semaglutide

Brand names: Ozempic (diabetes), Wegovy (weight), Rybelsus (oral, diabetes)
FDA status: Approved
Cost: $900–1,400/month list price; insurance coverage variable
Compounding: Available through licensed compounding pharmacies with prescription (during shortage periods)
Availability: Widely available; shortage periods have occurred

Tirzepatide

Brand names: Mounjaro (diabetes), Zepbound (weight)
FDA status: Approved
Cost: $1,000–1,300/month list price
Compounding: Available through licensed compounding pharmacies with prescription
Availability: Widely available; some shortage periods

Retatrutide

Brand names: None yet (investigational)
FDA status: Phase 3 clinical trials
Cost: Not commercially available
Compounding: Not available — investigational compounds cannot be compounded
Availability: Clinical trial enrollment only; potential approval 2027–2028

How to Choose

Semaglutide is the right starting point if:

You want the most established safety and efficacy data
Cardiovascular risk reduction is a priority (SELECT trial data)
Cost or insurance coverage is a constraint (more coverage options)
You're starting peptide therapy for the first time

Tirzepatide is worth considering if:

You've tried semaglutide and want greater efficacy
You're targeting more aggressive weight loss (20%+ body weight)
Your physician has experience with dual agonists
You have type 2 diabetes (superior HbA1c reduction data)

Retatrutide is not yet an option unless you qualify for and enroll in a clinical trial. If the Phase 3 data holds, it will likely become the most efficacious option in the class — but that's 2027–2028 at the earliest.

The Bigger Picture

These three compounds represent a fundamental shift in how medicine approaches obesity and metabolic disease. For decades, obesity was treated as a behavioral problem. These drugs demonstrate it has a strong biological component — and that biology can be targeted pharmacologically with remarkable results.

The pipeline doesn't stop at retatrutide. Oral GLP-1 agonists (orforglipron, danuglipron) are in late-stage trials. Combination approaches with amylin analogs (cagrilintide + semaglutide) are showing even greater efficacy. The next five years will likely see further step-changes in what's possible.

For current options, see our Clinic Directory for licensed providers offering these compounds, and the individual profiles for Semaglutide, Tirzepatide, and Retatrutide.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide or pharmaceutical therapy.